Human cancer therapy approaches are rapidly changing due to the successes of immunotherapy using drugs such as ipilimumab (anti-CTLA4), pembrolizumab (anti-PD-1), atezolizumab (anti-PD-L1), and tisagenlecleucel (CD19 CAR-T). Here, CD19 is linked to cancer.